Halozyme Expands ENHANZE Licensing Deal With argenx to Eight Targets

Key Facts

1Halozyme expanded its ENHANZE collaboration and licensing agreement with argenx to cover a total of eight targets.

2The expanded deal allows Halozyme to access new milestone payments and royalties as revenue growth accelerates.

Halozyme expanded its ENHANZE collaboration and licensing agreement with argenx to cover a total of eight therapeutic targets. Zacks reported that the expanded deal aims to leverage Halozyme's subcutaneous delivery technology for more of argenx's pipeline.

The expanded agreement allows Halozyme to access new milestone payments and royalties as revenue growth accelerates. This collaboration with a major partner provides clear long-term revenue visibility through milestone-based financial streams.